AARD: SEC Form 10-Q filed by Aardvark Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for AARD
Across the 6 sessions after earlier AARD headlines, the stock closed higher 1 times and lower 5 times, with a median move of 4.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AARD | SPY |
|---|---|---|---|
| Nov 14, 2025 | Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates | -8.7% | -0.0% |
| Nov 12, 2025 | Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) | -3.0% | +0.1% |
| Nov 7, 2025 | BTIG Research initiated coverage on Aardvark Therapeutics with a new price target | +2.7% | +0.1% |
| Nov 4, 2025 | Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025and 1 other headline that session | -5.7% | -1.2% |
| Nov 3, 2025 | Aardvark Therapeutics to Present at Upcoming Investor Conferences in November | -2.8% | +0.2% |
| Oct 22, 2025 | Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek | -8.3% | -0.5% |
Quantisnow market dataNASDAQ
AARD
Aardvark Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Get push alerts for AARD
Full AARD profile on Quantisnow Follow AARD and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time